211 related articles for article (PubMed ID: 35700934)
1. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study.
Hamid O; Eltelbany A; Mohammed A; Alsabbagh Alchirazi K; Trakroo S; Asaad I
Ann Hepatol; 2022; 27(5):100727. PubMed ID: 35700934
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
3. NAFLD and NASH are obesity-independent risk factors in COVID-19: Matched real-world results from the large PINC AI™ Healthcare Database.
Brozat JF; Ntanios F; Malhotra D; Dagenais S; Katchiuri N; Emir B; Tacke F
Liver Int; 2024 Mar; 44(3):715-722. PubMed ID: 38110709
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
5. Is cryptogenic cirrhosis different from NASH cirrhosis?
Thuluvath PJ; Kantsevoy S; Thuluvath AJ; Savva Y
J Hepatol; 2018 Mar; 68(3):519-525. PubMed ID: 29162389
[TBL] [Abstract][Full Text] [Related]
6. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
8. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
9. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
12. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study.
Ghoneim S; Dhorepatil A; Shah AR; Ram G; Ahmad S; Kim C; Asaad I
World J Hepatol; 2020 Jul; 12(7):378-388. PubMed ID: 32821336
[TBL] [Abstract][Full Text] [Related]
18. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
[TBL] [Abstract][Full Text] [Related]
19. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016.
Golabi P; Bush H; Stepanova M; Locklear CT; Jacobson IM; Mishra A; Trimble G; Erario M; Venkatesan C; Younossi I; Goodman Z; Younossi ZM
Medicine (Baltimore); 2018 Aug; 97(31):e11518. PubMed ID: 30075518
[TBL] [Abstract][Full Text] [Related]
20. Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States.
Ruiz-Casas L; Pedra G; Shaikh A; Franks B; Dhillon H; Fernandes JDDR; Mangla KK; Augusto M; Schattenberg JM; Romero-Gómez M
Medicine (Baltimore); 2021 Dec; 100(50):e28165. PubMed ID: 34918671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
